Fuzheng Nizeng Formula for Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia, a Multicenter Randomized Controlled Trial

Last updated: March 21, 2024
Sponsor: Peking University First Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neoplasms

Bowel Dysfunction

Ulcers

Treatment

Moluodan granules

Fuzhegn Nizeng Decoction

Clinical Study ID

NCT06324825
2022CR64
  • Ages > 18
  • All Genders

Study Summary

Fuzheng Nizeng Formula (FZNZ) is derived from the classic formula Liujunzi Decoction. Former pilot study found that FZNZ promoted the recovery of gastric atrophy and relieve the relative symptoms. This study is to evaluate its efficacy for chronic atrophic gastritis with low-grade intraepithelial neoplasia, compared with positive control Molduodan granule.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Chronic Atrophic Gastritis With Low-grade Intraepithelial Neoplasia diagnosed byendoscopy and stomach biopsy.
  • Helicobacter pylori negative.
  • TCM syndrome is spleen-stomach deficiency with blood stasis and phelgm.

Exclusion

Exclusion Criteria:

  • History of gastric surgery.
  • Combined with malignant tumor.
  • History of mental illness.
  • Allergy to any components of the drug use in the study.
  • Planning to pregnancy, or pregnant woman and lactating woman.

Study Design

Total Participants: 144
Treatment Group(s): 2
Primary Treatment: Moluodan granules
Phase:
Study Start date:
October 24, 2022
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Peking University First Hospital

    Beijing, Beijing 100034
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.